Pharma BD Deal Intelligence

AbbVie Inc. / RemeGen Co., Ltd.

2026 · Licensing/Option · $5.6B · Complete

AbbVie and RemeGen announced an exclusive licensing agreement for the development, manufacture and commercialization of RC148, an investigational PD-1/VEGF-targeted bispecific antibody being developed as monotherapy and in combination across multiple advanced solid tumors. AbbVie receives exclusive rights outside the Greater China territory. RemeGen receives USD 650M upfront and is eligible for up to USD 4.95B in milestones plus tiered double-digit royalties.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  AbbVie Inc. deals